Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Regulatory
Approvals worldwideDrug spendingDrug targets
Regulatory · NICE technology appraisal guidance · England

NICE technology appraisals

Every medicine and treatment NICE has appraised for the NHS in England since 2000: NICE's recommendation, when it was published, whether it still stands, and a link to the guidance and to the medicine's trials on this site.

Source: NICE technology appraisal guidance and NICE's appraisal recommendations data, shown with NICE's permission. Checked 3 Oct 2026
1,189Technology appraisals published
90%Of 897 current decided appraisals recommend for at least some patients
72Published in 2026 so far
976Linked to a medicine page here
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from NICE technology appraisal guidance · Last verified · Editorial standards

NICE has published 1,189 technology appraisals since 2000, and 1,062 of them are still current. Of the current appraisals where NICE reached a decision, 90% recommend the medicine or treatment for at least some patients, including through the Cancer Drugs Fund. The most recent is TA1189, published 26 Aug 2026. NICE's decisions apply to the NHS in England; in Ireland the HSE decides on reimbursement, advised by the National Centre for Pharmacoeconomics.

01

What NICE decided

Appraisals by recommendation type

An appraisal can contain several recommendations, for different groups of patients, so it can appear under more than one type. These explanations are ours; NICE's own definitions are on nice.org.uk.

02

Only in research

23 appraisals, newest first
AppraisalMedicine pageNICE recommendationPublishedStatus
Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia
NICE TA733
InclisiranOptimised Only in research6 Oct 2021Current
Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban
NICE TA697
—Optimised Only in research12 May 2021
Updated 15 Jan 2025
Current
Intrabeam radiotherapy system for adjuvant treatment of early breast cancer
NICE TA501
—Only in research31 Jan 2018Current
Holoclar for treating limbal stem cell deficiency after eye burns
NICE TA467
—Optimised Only in research16 Aug 2017Current
Dapagliflozin in combination therapy for treating type 2 diabetes
NICE TA288
DapagliflozinRecommended Only in research26 Jun 2013
Updated 23 Nov 2016
Current
Roflumilast for the management of severe chronic obstructive pulmonary disease
NICE TA244
RoflumilastOnly in research25 Jan 2012Current
Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia
NICE TA193
RituximabOptimised Only in research28 Jul 2010Current
Endovascular stent–grafts for the treatment of abdominal aortic aneurysms
NICE TA167
—Recommended Only in research25 Feb 2009Current
Spinal cord stimulation for chronic pain of neuropathic or ischaemic origin
NICE TA159
—Only in research Optimised22 Oct 2008Current
Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease
NICE TA111
Donepezil, Galantamine, MemantineOptimised Only in research22 Nov 2006Current
Computerised cognitive behaviour therapy for depression and anxiety
NICE TA97
—Not recommended Recommended Only in research22 Feb 2006Withdrawn
Colorectal cancer (advanced) - irinotecan, oxaliplatin and raltitrexed
NICE TA93
Irinotecan, Oxaliplatin, RaltitrexedRecommended Only in research24 Aug 2005Current
HealOzone for the treatment of tooth decay (occlusal pit and fissure caries and root caries)
NICE TA92
—Only in research27 Jul 2005Current
The use of autologous chondrocyte implantation for the treatment of cartilage defects in the knee joints
NICE TA89
—Only in research25 May 2005Replaced by TA477
The clinical effectiveness and cost effectiveness of anakinra for rheumatoid arthritis
NICE TA72
AnakinraOnly in research26 Nov 2003Current
Rituximab for aggressive non-Hodgkin's lymphoma
NICE TA65
RituximabRecommended Only in research24 Sep 2003Current
Computerised cognitive behaviour therapy (CCBT) for the treatment of depression and anxiety
NICE TA51
—Only in research24 Oct 2002Replaced by TA97
Guidance on the use of metal on metal hip resurfacing arthroplasty
NICE TA44
—Only in research26 Jun 2002Replaced by TA304
The clinical effectiveness and cost effectiveness of rituximab for follicular lymphoma
NICE TA37
RituximabOnly in research Not recommended27 Mar 2002Current
The clinical effectiveness and cost effectiveness of irinotecan, oxaliplatin and raltitrexed for colorectal cancer
NICE TA33
Irinotecan, Oxaliplatin, RaltitrexedNot recommended Recommended Optimised Only in research27 Mar 2002Replaced by TA93
Laparoscopic surgery for colorectal cancer
NICE TA17
—Only in research16 Dec 2000Replaced by TA105
Autologous cartilage transplantation for full thickness cartilage defects in knee joints
NICE TA16
—Only in research16 Dec 2000Replaced by TA89
Liquid-based cytology for cervical screening
NICE TA5
—Only in research26 Jun 2000Replaced by TA69

Titles link to the guidance on nice.org.uk, where the full recommendations are. A medicine is linked to its page here only when the name NICE appraised is exactly the same molecule as ours; medicines given alongside it (“with chemotherapy”) are not counted as appraised. Appraisals of devices and procedures are listed but have no medicine page.

© NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

Medicines data, weekly

One email every Friday: new approvals, trials and shortages, with every figure linked to its source.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

NICE has allowed us to show the appraisal number, title, recommendation category and dates of each technology appraisal, with a link to the guidance. No guidance text is reproduced.

A nightly job reads NICE's recommendations data, reads each new appraisal page once and re-checks every page every 60 days for replaced or withdrawn guidance. It keeps the previous version if a refresh fails. No AI drafting. See our methodology. The NICE data on this page was last retrieved on 3 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.